Le glioblastome.

IDH; MGMT; Radiotherapy; Surgery; Glioblastoma; Biomarkers, Tumor; DNA Methylation; Humans; Mutation; Neoplasm Recurrence, Local/genetics; Prognosis; Brain Neoplasms/therapy; Glioblastoma/genetics; Glioblastoma/therapy; Brain Neoplasms; Neoplasm Recurrence, Local; Medicine (all)

Abstract :

[en] Glioblastoma is the most common primary malignant brain tumor. Despite treatments combining excisional surgery, chemotherapy, and radiotherapy, overall survival remains low and the incidence of tumor recurrence remains high. Advances in the understanding of the disease, particularly its molecular biology and the mechanisms of action of systemic and radiotherapeutic treatments, as well as the development of image-guided surgical techniques, offer hope for the control of this hitherto incurable disease.
[fr] Le glioblastome est la tumeur cérébrale maligne primitive la plus fréquente. Malgré des traitements combinant la chirurgie d’exérèse, la chimiothérapie et la radiothérapie, la survie globale reste faible avec une incidence élevée de récidive tumorale. Les progrès dans la compréhension de la maladie, et en particulier de la biologie moléculaire et des mécanismes d’action des traitements systémiques et radiothérapeutiques, de même que le développement des techniques chirurgicales guidées par l’image, permettent d’entrevoir un espoir dans le contrôle de cette maladie jusqu’ici incurable.

Disciplines :

Oncology

Author, co-author :

Martin, Didier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurochirurgie

Bianchi, Elettra ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anatomie et cytologie pathologiques

Ben Mustapha, Selma ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiothérapie

Freres, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale

Language :

French

Title :

Le glioblastome.

Alternative titles :

[en] Glioblastoma.

Publication date :

May 2021

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Revue Medicale de Liege, Belgium

Volume :

Issue :

5-6

Pages :

419 - 424

Peer reviewed :

Editorial Reviewed verified by ORBi

Available on ORBi :

since 11 January 2023

Statistics

Number of views

297 (9 by ULiège)

Number of downloads

1106 (16 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Shinoda J, Sakai N, Murase S, et al. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001;52:161-71.
Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 2014;232:165-77.
Shergalis A, Bankhead A 3rd, Luesakul U, et al. Current Challenges and opportunities in treating glioblastoma. Pharmacol Rev 2018;70:412-45.
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
Pollo B. Neuropathological diagnosis of brain tumours. Neurol Sci.2011;32(Suppl 2):209-11.
Bailey P, Cushing H. A classification of the tumours of the glioma group on a histogenetic basis, with a correlated study of prognosis. British J Surgery 1927;14:554-5.
Goffart N, Lombard A, Lallemand F, et al. CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro Oncol 2017;19:66-77.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803-20.
Li R, Li H, Yan W, et al. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget 2015;6:7318-24.
Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53.
Lee DH, Ryu HW, Won HR, Kwon SH. Advances in epigenetic glioblastoma therapy. Oncotarget 2017;8:18577-89.
Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 2016;20:1-8.
Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 2014;23:1985-96.
Ellor SV, Pagano-Young TA, Avgeropoulos NG. Glioblastoma: background, standard treatment paradigms, and supportive care considerations. J Law Med Ethics 2014;42:171-82.
Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther 2015;152:63-82.
Greenberg MS. Handbook of Neurosurgery. 9ème éd. Stuttgart:Thieme Medical Publishers;2019.
Schiff D, Lee EQ, Nayak L, et al. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol 2015;17:488-504.
Perry J, Zinman L, Chambers A, et al. The use of prophylactic anticonvulsants in patients with brain tumours-a systematic review. Curr Oncol 2006;13:222-9.
Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;54:1886-93.
Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993;79:533-6.
Reuter G, Moïse M, Roll W, et al. Conventional and advanced imaging throughout the cycle of care of gliomas. Neurosurg Rev 2021;doi: 10.1007/s10143-020-01448-3.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
Grabowski MM, Recinos PF, Nowacki AS, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 2014;121:1115-23.
Keles GE, Anderson B, Berger MS. The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 1999;52:371-9.
Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
Kubben PL, Scholtes F, Schijns OE, et al. Intraoperative magnetic resonance imaging versus standard neuronavigation for the neurosurgical treatment of glioblastoma: A randomized controlled trial. Surg Neurol Int 2014;5(Supplement):70.
Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401.
Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol Off J Eur Soc Med Oncol 2013;24:3117-23.
Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015;129:133-46.
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
Salazar OM, Rubin P, Feldstein ML, Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys 1979;5:1733-40.
Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.
Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Oncol 2002;64:259-73.
Minniti G, Niyazi M, Alongi F, et al. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 2021;16:36.
Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol Off J Am Soc Clin Oncol 2004;22:1583-8.
Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017;376:1027-37.
Mann J, Ramakrishna R, Magge R, Wernicke AG. Advances in radiotherapy for glioblastoma. Front Neurol 2018;8:748.
Ellis HP, Greenslade M, Powell B, et al. Current challenges in glioblastoma: Intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front Oncol 2015;5:1-9.
Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
Iwamoto FM, Fine HA. Bevacizumab for malignant gliomas. Arch Neurol 2010;67:285-8.
Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2019;20:110-9.
Liu D, Offin M, Harnicar S, et al. Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag 2018;14:1247-52.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731-9.
Schreck KC, Guajardo A, Lin DD, et al. Concurrent BRAF/ MEK inhibitors in BRAF V600-Mutant high-grade primary brain tumors. J Natl Compr Cancer Netw 2018;16:343-7.
Kaley T, Touat M, Subbiah V, et al. BRAF inhibition in BRAFV600-mutant gliomas: Results from the VE-BASKET study. J Clin Oncol 2018;36:3477-84.
Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016;375:2561-9.
Desjardins A, Gromeier M, Herndon JE, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:150-61.
Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. JAMA 2017;318:2306-16.